Skip to main content
Figure 3 | BMC Medical Genomics

Figure 3

From: Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells

Figure 3

Induction of APC and FAS expression and attenuation of beta-catenin and ERBB2 pathways by clorgyline in E-CA-88 cells. (A) APC and FAS expression was increased by clorgyline at all three points of the time course determined by qRT-PCR. (B) Expression changes of genes in beta-catenin pathway signatures in response to clorgyline. (C) Expression changes of genes in ERBB2 pathway signatures in response to clorgyline treatment. For both (B) and (C), red indicates higher expression in treated vs. control E-CA-88 cells, and green indicates lower expression. Only changes ≥ 2-fold were displayed. The degree of color saturation corresponding to the fold change is shown at the bottom of the images. (D) Number of genes overlapping between those whose expression changed ≥ 2-fold after clorgyline treatment and beta-catenin pathway signature. (E) Number of genes overlapping between those whose expression changed ≥ 2-fold after clorgyline treatment and ERBB2 pathway signature. For both (D) and (E), bars above the X-axis represent genes upregulated by clorgyline and bars below the X-axis downregulated. Asterisk indicates statistical significance by Chi-square test.

Back to article page